Abstract
In vivo investigation of onco/suppressor gene effects may provide new findings concerning chemical carcinogenesis. In earlier studies we pointed out the carcinogenic potential of COPP and ABVD chemotherapeutical protocols in "long-term" experiments. In another follow up study we proved the connection between the early gene expression changes and the late consequences of COPP and ABVD treatment during, a one year latency period. CHOP protocol is containing both proved carcinogenic cyclophosphamide and highly mutagenic doxorubicyn. CHOP protocol in "short-term" experiments shows strong effect on Ha-ras oncogene expression.
MeSH terms
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Cyclophosphamide / pharmacology
-
Doxorubicin / pharmacology
-
Female
-
Gene Expression / drug effects
-
Genes, myc / drug effects*
-
Genes, myc / genetics
-
Genes, p53 / drug effects*
-
Genes, p53 / genetics
-
Genes, ras / drug effects*
-
Genes, ras / genetics
-
Male
-
Mice
-
Mice, Inbred CBA
-
Oncogene Protein p21(ras) / metabolism
-
Oncogene Protein p55(v-myc) / metabolism
-
Prednisone / pharmacology
-
RNA / metabolism
-
Spleen / drug effects*
-
Thymus Gland / drug effects*
-
Tumor Suppressor Protein p53 / metabolism
-
Vincristine / pharmacology
Substances
-
Oncogene Protein p55(v-myc)
-
Tumor Suppressor Protein p53
-
Vincristine
-
RNA
-
Doxorubicin
-
Cyclophosphamide
-
Oncogene Protein p21(ras)
-
Prednisone